Trial reportThe American journal of gastroenterology2011
A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.
Trial report in The American journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Recommendations for the management of hepatitis C virus infection among people who inject drugs.The International journal on drug policy · 2015Guideline
- Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.The International journal on drug policy · 2015Pooled it
- Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review.International journal for equity in health · 2013Pooled it
- Hepatitis C Cascade of Care in a Multidisciplinary Substance Use Bridge Clinic Model in Tennessee.Open forum infectious diseases · 2024Article
- Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.JAMA network open · 2023Article
- History of alcohol use does not predict HCV direct acting antiviral treatment outcomes.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Experiences of an HCV Patient engagement group: a seven-year journey.Research involvement and engagement · 2021Review
- Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis.The International journal on drug policy · 2020Article
- Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.Liver international : official journal of the International Association for the Study of the Liver · 2019Review
- Associating conditional cash transfer to universal access to treatment could be the solution to the HCV epidemic among drug users (DUs).Harm reduction journal · 2018Article
- Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.International journal of psychiatry in medicine · 2018Article
- Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018Article
- Observational
- Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Nature reviews. Gastroenterology & hepatology · 2017Review
- Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.The International journal on drug policy · 2017Article
- Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Addictive disorders & their treatment · 2017Article
- Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections.World journal of hepatology · 2016Review
- An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.The International journal on drug policy · 2015Article
- What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?World journal of virology · 2015Review
- Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesMental health and substance abuse (MH/SA) comorbidities are the most oft-cited reasons for deferral from peginterferon (PegIFN) therapy for chronic hepatitis C virus (HCV). We sought to determine whether an integrated care intervention (INT) for patients deferred from PegIFN owing to MH/SA could improve subsequent treatment eligibility rates.
methodsIn this randomized controlled trial, 101 HCV patients who were evaluated at two hepatology centers and deferred from antiviral therapy owing to MH/SA were enrolled. Participants were randomized to an INT (N=50) or standard of care (SC; N=51). The INT group received counseling and case management for up to 9 months. All participants underwent 3-, 6-, and 9-month clinical follow-up visits, where hepatologists, masked to group, re-evaluated patients for treatment eligibility. Standardized mood and alcohol use instruments were administered to all participants to aid clinicians in treatment decisions.
resultsOf 101 participants, the mean age was 48 years and 50% were men, 61% Caucasian, and 77% genotype 1. Patients were initially deferred owing to psychiatric issues (35%), alcohol abuse (31%), drug abuse (9%), or more than one of these reasons (26%). In an intent-to-treat analysis, 42% (21/50) of INT participants became eligible for therapy compared to 18% (9/51) of SC participants (P=0.009, relative risk (RR)=2.38, 95% confidence interval (CI) (1.21, 4.68)). When baseline predictors significant at P<0.10 in univariate models were entered into multivariate models adjusted for treatment group, only baseline depression remained significant (P=0.05, RR=0.98, 95% CI (0.96, 1.00)). With the exception of a model adjusted for genotype, treatment group remained significant in all models.
conclusionsThis trial suggests that INTs can increase eligibility for HCV treatment and expand treatment to the underserved population with MH/SA comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.